Study of bempedoic acid in Italy
Treatments studied
Part of Hormones & metabolism clinical trials.
This study is checking how well people stick with taking bempedoic acid, a cholesterol-lowering medication, and how effective it is over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking bempedoic acid.
- You are between 18 and 80 years old.
- You are willing to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well people stick with and respond to the cholesterol-lowering drug Inclisiran. It aims to understand if the medicine works well over time in Italian patients.
This trial tests a triple combination of medications (bempedoic acid, ezetimibe, and a high-intensity statin) in people who have never had a heart attack or stroke but have moderate to severe coronary artery disease. The goal is to see if this combination lowers cholesterol and reduces future heart risks more effectively than standard care.
This study tests whether pemafibrate, a new medication, can lower cholesterol better when added to statin treatment in patients whose cholesterol remains high despite taking statins regularly. The goal is to see if this combination reduces heart disease risk.
This study tests whether adding a medication called bempedoic acid to standard cholesterol-lowering pills is better at lowering cholesterol after a heart attack. If you have recently had a heart attack and are already on statins, this might be an option to help prevent future heart problems.
This study tracks how well patients stick to and benefit from alirocumab 300mg, a cholesterol-lowering injection. It looks at real-world use in Italy.
This trial tests a drug called bempedoic acid to see if it can safely help lower cholesterol in adults. It may be an option if you have high cholesterol and need a different treatment.
Hear when a new Hypercholesterolemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.